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AbstrAct
Introduction Differences between the opinions of patients 
and physicians on the impact of asthma are common. We 
hypothesised that patient–physician discordance may 
negatively affect asthma outcome.
Methods A total of 2902 patients (61% women, mean 
age 47 years) with moderate–severe asthma and 231 
physicians participated in a prospective study. At the 
baseline visit, data on demographics, clinical variables, 
degree of asthma control according to the Asthma Control 
Test (ACT), basic spirometry and the Hospital Anxiety and 
Depression Scale (HADS) were collected and an ad hoc 
questionnaire was completed that allowed the degree of 
concordance between doctors and patients to be assessed. 
A scheduled telephone call after 3 months was used to 
elicit the ACT score and the future risk of asthma. At the 
final visit at 6 months, the following data were recorded: 
ACT score, spirometry, HADS score and an ad hoc 
questionnaire to assess the agreement between the doctor 
and the patient. Changes in study variables according 
to patient–physician concordance or discordance were 
analysed.
results The rate of patient–physician discordance 
was 27.2%, with overestimation of disease impact by 
the physician in 12.3% and underestimation in 14.9%. 
Patient–physician opinion discordance, particularly in 
the case of physicians underestimating the impact of 
asthma, showed worse results with statistically significant 
differences in ACT score, a higher percentage of patients 
with poor asthma control and lower HADS scores. The 
need for hospital and emergency department admissions 
was also higher.
conclusion Patient–physician opinion discordance 
may be contributing to lower symptomatic control 
and increased future risk, with a higher impact when 
physicians underestimate the impact of asthma on their 
patients.
IntroductIon
Asthma is a heterogeneous chronic inflam-
matory airways disease that represents a 
major public health problem, with a high 
prevalence and increasing trends in morbidity 
and mortality.1 Clinical practice guidelines 
for the management of asthma establish, as 
a primary objective of treatment, to achieve 
and maintain good control of symptoms and 
lung function, as well as to prevent future 
risk, including severe exacerbations, deterio-
ration of lung function and adverse effects of 
treatment.1–3
Although good control of asthma can be 
achieved in many patients, real-life studies 
have shown that asthma is frequently poorly 
controlled.4–6 Lack of patient involvement 
in treatment, partially attributed to poor 
communication with their physician, has been 
put forward as one of the reasons for inappro-
priate management of asthma.7–10 Ensuring 
the necessary involvement of patients in their 
treatment, which enables them to learn about 
key aspects of asthma including how to adapt 
their lifestyle to the disease and awareness of 
the expected benefits of treatment, improves 
the effectiveness of the patient–doctor rela-
tionship and consequently the adherence to 
asthma medication regimens. For all of these 
aspects, asthma clinical practice guidelines 
recommend maximising concordance between 
patients and healthcare professionals.1–3 The 
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term ‘concordance’ in different studies encompasses the 
level of agreement between physicians and patients in 
terms of general expectations from treatment and with 
regard to the disease. This means that patients should 
understand the potential benefits and limitations of treat-
ment as well as adverse events, whereas physicians ought 
to understand the perceptions and concerns of patients.11 
Therefore, the term includes a process in which physicians 
and patients agree on therapeutic decisions, recognise that 
they may have different perspectives, and the need to work 
together in the management of the disease to improve 
mutual understanding.12 In fact, unrealistically high or low 
expectations among patients concerning improvement of 
disease or the care they can receive from professionals may 
negatively affect patient–physician concordance.13
Despite the potential impact of misunderstandings 
between patients and physicians, only a few studies have 
examined concordance between patients’ and their 
doctors’ expectations in asthma.14 15 In a previous study of 
1160 patients with asthma and 300 pulmonologists, the rate 
of patient–pulmonologist concordance on disease impact 
on patient daily life was 57%, with physicians underes-
timating the impact (compared with patients) in 26% of 
cases, and in patient satisfaction with treatment of 56%.11 
However, no studies have previously assessed patients' and 
doctors' misperceptions in relation to control of asthma 
symptoms, future risk and comorbidities such as anxiety 
and depression. Anxiety and depression have been shown 
to correlate with poorly controlled asthma, reduced quality 
of life and increased healthcare use.16–19
The present prospective observational study was 
conducted to assess the impact of discordance in patients' 
and physicians' opinions on control of asthma symptoms, 
future risk and anxiety and depression. We hypothesised 
that patient–physician discordance may negatively affect 
asthma outcome, which consequently would reinforce 
the need to improve patient–physician concordance as a 
behavioural aspect of asthma education.
Methods
study design
This was a prospective, observational, multicentre study 
with a follow-up period of 6 months. The study was carried 
out in 174 hospitals throughout Spain belonging to the 
public National Healthcare System. A total of 231 inves-
tigators were recruited for the study, 121 of whom were 
specialists in allergology, 103 in pneumology, 6 in general 
internal medicine and 1 in emergency medicine.
ethical aspects
The study was promoted by Mundipharma Pharma-
ceuticals (Madrid, Spain). It was carried out in accord-
ance with the 1991 International Guidelines for Ethical 
Review of Epidemiological Studies and complied with 
the updated version of the Declaration of Helsinki and 
Order SAS/3470/2009. The study was submitted to 
the Spanish Agency of Medicines and Health Products 
for classification, and the protocol was approved by 
the Ethics Committee of the participating hospitals of 
the study coordinators. Written informed consent was 
obtained from all patients. Study data were entered in a 
database owned by Mundipharma Pharmaceuticals, who 
were responsible to the Spanish Data Protection Agency 
(AEPD) and ensured confidentiality of data according to 
the Spanish law on Personal Data Protection (Organic 
Act 15/1999 December 13).
Population
Patients who attended the first visit with their specialist 
doctor were recruited from the outpatient clinics of 
the participating hospitals. The inclusion criteria were: 
previously diagnosed with asthma, male and female 
patients aged ≥18 years, moderate or severe persistent 
asthma (step ≥3 according to the Spanish Guidelines for 
the Management of Asthma (GEMA)),1 stable disease 
(patients had had no asthmatic exacerbations or changes 
in usual asthma treatment in the last 6 months), agreed 
to take part in the study and provided written informed 
consent. The diagnosis of asthma was based on patients 
reporting symptoms consistent with asthma (coughing, 
wheezing, chest tightness, shortness of breath) and 
a positive bronchodilator test (increase of ≥12% and 
≥200 mL as an absolute value compared with baseline in 
either forced expiratory flow in 1 s (FEV1) or forced vital 
capacity (FVC)) or a daily peak expiratory flow variability 
>20%, or a positive methacholine challenge test docu-
mented in the case history.20 Patients were excluded from 
the study if they had a concomitant disease (sarcoidosis, 
lung cancer, pulmonary tuberculosis, bronchiectasis, 
nephropathy, rheumatic or liver disease), significant 
comorbidity that could affect the study results in the 
physician’s judgement or a cognitive impairment that 
could limit their comprehension of the subject under 
study or their ability to participate.
Methodology
The study included a baseline visit, a telephone assess-
ment 3 months later and a final visit at 6 months. At base-
line, the following data were recorded for each patient: 
demographics (age and sex); clinical variables (level of 
education, marital status, smoking status, number of 
years since onset of asthma, severity of asthma); degree 
of asthma control according to the Asthma Control Test 
(ACT)21 (an ACT score ≥20 identified well-controlled 
asthma)3; basic spirometry using the predicted values 
for the Mediterranean population22; an ad hoc ques-
tionnaire composed of 10 items about the impact of the 
disease on patient activities of daily living and future asth-
ma-related risk; and the Hospital Anxiety and Depression 
Scale (HADS).23 Asthma control (ACT score) and future 
risk were also assessed at the 3-month telephone call.
At the final visit at 6 months, data recorded were 
the following: ACT score, lung function (spirometry), 
HADS score, an ad hoc questionnaire composed of 10 
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items about the impact of the disease on patient activ-
ities of daily living and future asthma-related risk. The 
HADS is a 14-item questionnaire, with seven items 
related to anxiety and seven items related to depression. 
Each item is scored from 0 to 3, scores for each subscale 
ranging from 0 to 21 and scores for the entire scale 
(emotional distress) from 0 to 42, with higher scores 
indicating more distress. HADS scores in each construct 
are divided into normal (0–7), doubtful (8–10) and 
definite (11–21) cases.17 The ad hoc questionnaire was 
composed of 10 items about the impact of the disease on 
patient activities of daily living; each item was scored on 
a Likert scale ranging from 0 (no impact) to 10 (severe 
impact) (see table 1). The 10-item questionnaire on 
the impact of asthma on daily living was completed by 
the patients and also by the physicians using the infor-
mation available in each patient’s medical history and 
their knowledge of the case after seeing the patient. To 
use this questionnaire, this study took as reference the 
study by Urrutia et al.11 Physicians were blinded to the 
patients' responses to questions. The physicians were 
given access to the responses of their patients after 
completing the questionnaires and, subsequent to the 
visit, they completed the online database. Comparison 
of the responses of the physician and the patient was 
performed by external observers through online and 
deferred registration in order to assess the degree of 
concordance between doctors and patients. The future 
risk of asthma was assessed according to the concepts 
established by the Global Initiative for Asthma (GINA)3 
and GEMA.1 These criteria are: (1) the number of 
severe asthma exacerbations in the previous 3 months 
(need for a short course of oral prednisone during 
a minimum of 3 days and/or visit to the emergency 
department and/or admission to the hospital); and (2) 
use of healthcare resources in the previous 3 months 
(visits to the primary care physician, specialist, nurse, 
emergency department and hospitalisations).
statistical analysis
The sample size needed to allow evaluation of the main 
objective of the study was based on the study by Urrutia 
et al.11 In this cross-sectional design work, the level of 
concordance between patients and doctors ranged 
between 57% and 75%. Therefore, for a type I error of 
0.05 and amplitude of the 95% CI of 3.5%, a total of 3075 
patients would be needed in the case of 57% concord-
ance (worst scenario). Since the patients had a follow-up 
of 6 months in the study, the sample size was increased 
to allow for possible losses in follow-up. A loss rate of 5% 
was assumed, so an attempt was made to include 3250 
patients in the study. Categorical variables are expressed 
as absolute and relative frequencies and quantitative 
variables as mean, median, SD, min, max, Q1 and Q3. 
To assess the level of agreement between patients and 
physicians in responses to the 10-item questionnaire of 
the impact of asthma on daily activities, an algorithm that 
classified cases into concordance or discordance of opin-
ions was used. Patient–physician opinion agreement or 
concordance was established when the mean of the sum 
of scores of physicians' and patients' questionnaires was 
in the same quartile, and lack of agreement or discord-
ance when they did not coincide in the same quartile. 
In case of discordance, underestimation or overestima-
tion was considered when physicians scored below or 
above the patients’ scores, respectively. The difference 
in the total scores of physicians and patients was used 
to generate a new continuous variable (the higher the 
score, the greater the disagreement), which was explored 
with other continuous variables. Categorical variables 
were compared with the Χ2 test and the Fisher exact test 
Table 1 Description of the 10-item ad hoc questionnaire to assess the impact of asthma on daily living activities completed 
by patients and physicians
Items
Scores (from 0=no impact to 10=severe impact)
0 1 2 3 4 5 6 7 8 9 10
1. Having independence in self-care (personal hygiene/grooming, 
dressing/undressing, eating, etc)
2. Doing housework (cleaning including floors, making beds, etc)
3. Performing other normal daily activities (regular commitments, 
going out, hobbies, exercise, etc)
4. Performing sporadic leisure time activities (travelling, cinema/
theatre, sports, other hobbies, etc)
5. Carrying out usual work tasks
6. Maintaining normal social relationships
7. Maintaining normal family relationships
8. Having an active sexual life (frequency of relations and 
satisfaction)
9. Economic burden of the disease on the family
10. Health-related quality of life
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for independent samples, or the McNemar test for paired 
samples. Quantitative variables were compared with the 
Student t-test, the Mann–Whitney U test or the Wilcoxon 
rank-sum test. The analysis of variance (ANOVA) or the 
Kruskal–Wallis test was used for the comparison of three 
or more groups of continuous data. The relationship 
between two continuous variables was assessed using the 
Spearman rank-order correlation coefficient (ρ). Statis-
tical analysis was performed using the Statistical Package 
for Social Sciences (SPSS, Chicago, Illinois, USA) Version 
22.0 for Windows. The threshold for statistical signifi-
cance was set at p<0.05.
results
sociodemographic and clinical characteristics of patients
A total of 3183 patients diagnosed with asthma were 
included in the study, but 281 (8.8%) failed to complete 
the 6-month follow-up. The main cause of patients’ loss 
to follow-up was abandonment of the study (failure to 
attend the medical visit). Therefore, the study population 
consisted of 2902 patients (61.2% women) with a mean 
(SD) age of 46.8 (16.7) years. Salient findings were as 
follows: 63.9% of patients were never smokers, 65.4% 
were married or lived with a partner and 31.7% had 
completed secondary education. Asthma-related data at 
baseline showed a poor control of symptoms in 75.3% 
of patients (ACT score <20), the mean (SD) forced 
expiratory volume in 1 s (FEV1) was 81.6 (20.9)% and 
persistent moderate asthma was diagnosed in 81% of 
patients. Anxiety and depression were present in 24.2% 
and 11.7% of patients, respectively. At 6 months there 
was a significant improvement in asthma control, degree 
of airways obstruction and anxiety and depression scores 
according to the HADS (table 2).
Patient–physician opinion concordance/discordance
At the follow-up visit at 6 months, discordance between 
patients' and physicians' opinions was found in 789 
(27.2%) cases. The impact of asthma on daily living was 
underestimated by the physician in 357 (12.3%) cases 
Table 2 Sociodemographic data, spirometry, level of control of asthma symptoms and anxiety/depression of study patients
Variables
Baseline visit
(n=3183)
Telephone survey 
at 3 months
(n=3057)
Final visit at 
6 months
(n=2902)
p Value (final 
vs baseline 
visits)
Sociodemographic data
  Women, n (%) 1948 (61.2)
  Age, years, mean (SD) 46.8 (16.7)
  Smoking status
   Current smoker 391 (12.3)
   Ex-smoker 757 (23.8)
   Never smoker 2034 (63.9)
   Civil status
   Married or lived with a partner 2082 (65.4)
   Single 820 (25.8)
   Separated or widowed 281 (8.8)
  Years since asthma diagnosis, mean (SD) 7.6 (9.6)
  Severity of asthma, n (%)
   Moderate 2577 (81.0)
   Severe 605 (19.0)
Exacerbations in the last 6 months, mean (SD) 2.3 (1.8)
Asthma control and spirometry
  ACT score, mean (SD) 15.8 (4.7) 19.3 (4.2) 19.4 (4.4) <0.001
  Patients with controlled asthma (ACT ≥20), n (%) 785 (24.7) 1700 (55.6) 1667 (57.5) <0.001
  FEV1, %, mean (SD) 81.6 (20.9) 86.0 (20.8) <0.001
HADS
  Anxiety subscale score, mean (SD) 7.1 (4.3) 5.9 (4.2) <0.001
  Patients with anxiety (score ≥11), n (%) 769 (24.2) 445 (15.3) <0.001
  Depression subscale score, mean (SD) 5.2 (4.1) 4–4 (4.0) <0.001
  Patients with depression (score ≥11), n (%) 373 (11.7) 234 (8.1) <0.001
ACT, asthma control test; FEV1, forced expiratory volume in first second; HADS, Hospital Anxiety Depression Scale.
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and overestimated in the remaining 432 (14.9%). As 
shown in table 3, in the group with patient–physician 
discordance, in particular due to underestimation of 
the impact of the disease by physicians, poorer results 
of asthma outcome were obtained, with statistically 
significant differences in the control of symptoms (ACT 
score and percentage of patients with poorly controlled 
asthma) and level of anxiety and depression. Also, the 
amplitude of the difference between patients' and physi-
cians' scores was significantly and negatively associated 
with asthma control (ACT test) (ρ=−0.322, p<0.001) and 
significantly and positively associated with the number 
of exacerbations (ρ=0.171, p<0.001) and overall HADS 
scores (ρ=0.275, p<0.001).
dIscussIon
This study shows that discordance in the opinion of 
patients with asthma and their physicians regarding the 
impact of disease on activities of daily living is relatively 
frequent (27.2% of cases) and is associated with a poorer 
symptomatic control of asthma and also, in part, with a 
higher future risk, especially when the physician has under-
estimated the impact of the disease. This finding may have 
important implications in asthma education programmes, 
in which it seems necessary to include strategies for 
improving differences between patients and clinicians in 
their views regarding repercussions of the disease in daily 
life. It is possible that these differences of opinion may have 
implications for the difficulty in achieving good asthma 
control. Clinicians in their usual clinical practice should 
consider these results. New tools should be established in 
the consultation to improve this aspect.
Despite clinical practice guidelines with explicit recom-
mendations for a stepwise approach tailored to disease 
severity1–3 and validated instruments to assess the degree 
of asthma control,21 24 25 different studies have shown 
that, in less than 40% of patients, asthma is well-con-
trolled.26 27 Patients with inadequately controlled asthma 
often have limited therapeutic options and remain at 
high risk of serious morbidity and mortality.28 However, 
patients’ misperceptions regarding the presence of symp-
toms as indicative of poor asthma control is frequent. An 
online survey conducted among 8000 patients with asthma 
from 11 European countries showed interesting data.29 
More than 80% of respondents considered their asthma 
to be controlled and over two-thirds did not regard their 
condition as serious, even among those whose asthma was 
uncontrolled according to the GINA criteria.3 Similarly, 
more than 80% of respondents who had experienced acute 
exacerbations (oral steroid use, emergency department 
visits or hospitalisations) in the previous year regarded 
their asthma as controlled. Of those who considered their 
asthma controlled, 55.5% had had symptoms that inter-
fered with normal activities and 52.5% had awoken at 
night because of asthma in the previous week. Moreover, 
of those who regarded their asthma as not serious, 19.5% 
reported an asthma-related emergency department visit in 
the previous year. Educating patients will help to improve 
their understanding of asthma and enable them to work 
with their physician to manage their disease.29
It has been shown that patients, particularly those 
with severe and/or difficult asthma and poor control, 
underplay symptoms and do not discuss non-medical 
factors which may impact on asthma control in primary 
care consultations,4 so training physicians in the use 
of patient-centred communication skills may optimise 
asthma management in this setting. Moreover, poor 
professional–patient communication has been consid-
ered a reason for the poor uptake of self-management 
plans and guideline use in general practice and primary 
care.7 Irwin and Richardson8 concluded that patient-fo-
cused care communication, continuity of care and 
concordance (finding common ground) are highly rele-
vant to the effective treatment of pulmonary disease and 
should be a key component of asthma management.
In a previous study of agreement between patients and 
pneumologists, patient–physician discordant rates of 
disease impact on daily life and patient satisfaction were 
significantly lower among patients with controlled asthma 
(29% and 32.1%) than those with poorly controlled 
disease (73.7% and 73.1%).11 In our study, patient–physi-
cian discordance was found in 27.2% of cases. The impact 
of asthma was overestimated by physicians in 12.3% of 
patients and underestimated in 14.9%. Patient–physi-
cian opinion discordance affected negatively the degree 
of asthma control, particularly when the patient’s status 
was underestimated by physicians. In addition, there was 
a significant negative correlation between patient–physi-
cian discordance and the ACT score.
Control of future risk includes the absence of severe 
exacerbation episodes and visits to the emergency 
department (or possible hospital admissions), preven-
tion of progressive deterioration of pulmonary function 
and dose adjustment of asthma medications to minimise 
adverse effects. In the present study, the amplitude of the 
difference in scores of the 10-item questionnaire between 
patients and physicians was significantly correlated with 
the number of exacerbations.
Different studies support the view that there is an increase 
in psychiatric morbidity in patients with obstructive airways 
diseases.30–35 A study carried out in adults with clinically 
stable asthma showed a prevalence of 36.9% for anxiety 
and 11% for depression,36 and both diseases were associ-
ated with poor asthma control. In our study, scores in the 
anxiety and depression subscales of the HADS improved 
significantly at 6 months compared with scores at baseline, 
after a timely visit by the doctor. Also, anxiety and depres-
sion scores were higher (more distress) when there was 
discordance between patients and physicians and the physi-
cian underestimated the impact of the patient’s disease. 
The amplitude of the difference in scores of the 10-item 
questionnaire between patients and physicians correlated 
significantly with anxiety and depression symptoms. The 
greater the discordance between patients' and physicians' 
opinions, the higher the degree of impairment due to 
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patients’ psychiatric comorbidity. This finding suggests the 
influence of physicians in the control of asthma of their 
patients and also in the degree of asthma-related anxiety 
and depression. In a study that compared opinions and 
involved 319 psychiatrists and 957 patients diagnosed 
with depression, depressive symptoms related to circadian 
rhythms (except fatigue, anergy and insensitivity) perceived 
by more than 65% of patients surveyed were significantly 
underestimated by psychiatrists and only partially resolved 
with antidepressive medication.37 On the other hand, satis-
faction with the results of treatment with antidepressants 
manifested by patients was lower than general satisfaction 
stated by psychiatrists.37 Other studies have also concluded 
that physicians evaluate differently the presence and impact 
of symptoms on daily activities of their patients and, in turn, 
the level of satisfaction and compliance with treatment.38–45
limitations and strengths
This study has some limitations. First, we have not included 
other measurements or variables that may affect the degree 
of asthma control, such as treatment adherence, adjust-
ment of maintenance treatment, patient’s education or use 
of non-invasive methods of measurement of airway inflam-
mation. Second, this study has a selection bias: both the 
pulmonologists and the patients volunteered to participate 
in the study. Third, the different medical specialists may 
have different perspectives on how to approach/educate/
treat patients with asthma. Finally, an important proportion 
of patients were active or previous smokers (36.1%) and 
some might have overlapping symptoms of COPD-asthma 
that could influence outcomes. However, since the mean 
age of the population was 46.8 years, it is less likely that 
these patients had COPD. However, the large sample size 
of 2902 patients who completed the 6-month follow-up 
period gives strength to the study findings.
conclusIons
Patient–physician opinion discordance related to the 
impact of asthma on patients’ daily activities may be 
contributing to lower symptomatic control and increased 
future risk, with a higher impact when physicians under-
estimate the impact of asthma on their patients.
Asthma education programmes should address 
patients' and doctors' discordances. Educational strate-
gies to promote an optimal level of concordance between 
patients' and physicians' opinions and expectations should 
be pursued.
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